Minor histocompatibility antigens (mHags) are involved in the induction of graft-versus-host disease (GVHD) after HLAidentical bone marrow transplantation. Previously, we isolated a series of HLA-A*0201+estricted cytotoxic T-cell (CTL) clones specific for the same mHag HA-l from peripheral blood of three unrelated patients who were suffering from GVHD. We have now analyzed the composition of the T-cell receptor (TCR) V regions of 12 of these mHag HA-l-specific HLA-A*0201-restricted CTL clones by DNA sequencing of the a and P chains. Of these 12 clones, derived from three unrelated individuals, five independent TCRaV-and PV-region sequences were established. The TCRa chains were composed of varying TCRaV and TCRaJ genes with no obvi-HE RESULTS in human bone marrow (BM) transplantation are still not satisfactory. Despite the selection of HLA-identical siblings as BM donors for patients with severe aplastic anemia or leukemia, graft-versus-host disease (GVHD) still occurs. This complication can be caused by disparity between donor and recipient for minor histocompatibility antigens (mHags). Besides the well known mHags H-Y, we previously characterized five nonsex-linked mHags designated HA-1, -2, -3, -4 and -5; all are recognized in a classical major histocompatibility complex (MHC)-restricted fashion.' Each of these mHags is a product of a single gene and shows a Mendelian mode of inheritance. These genes are not coded for within the MHC.' T-cell clones specific for these mHags were derived from the peripheral blood lymphocytes (PBLs) from patients suffering from GVHD. These cytotoxic T-cell (CTL) clones reacted most frequently against the mHag HA-l.' A series of HLA-A*0201-restricted CTL clones specific for the mHag HA-l exhibited identical reaction patterns in comprehensive immunogenetic studies, suggesting that they recognize the same mHag HA-1 .3 Evaluation of the impact of mHag HA-1 mismatching in 148 HLA-identical BM recipientldonor pairs on the development of GVHD showed a strong correlation between HA-l mismatch and GVHD.'"
ous similarities in structure in the N regions. However, the TCRP chains all used the TCRpVSS9 gene segment, and showed remarkable similarities within the N-D-N regions; ie, three independent P-chain sequences (originating from donors Ha and Gy) shared a leucinelvaline amino acid pair, whereas the other two (originating from donors Ha and Wi) shared a serinelthreonine pair, all at positions 99 and 100 of the TCRpV region. In conclusion, the TCR analysis of HA-1 mHag-specific CTL clones has shown that the HA-l mHagl HLA-A*0201 complex selects for highly similar TCRPV regions.
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Except for one piece of data in the murine system" reporting a dominant mHag response but no TCRPV bias during the development of a GVHD, there exists, to our knowledge, as yet no information on TCR usage of mHag-specific GVHDrelated CTL clones. The apparent immunogenicity of mHag HA-l reflected by the observed dominant responses post BMT as well as its correlation with GVHD makes the identification of the TCR structure recognizing this clinically important mHag MHC/peptide complex especially relevant. Here we report on the TCR analyses of 12 CTL clones, all specific for the MHC class VmHag HA-l peptide complex, derived from three unrelated individuals. A strong bias towards TCROV and N-D-N region usage in the recognition of the MHC/mHag HA-l complex was observed among the three unrelated patients investigated.
MATERIALS AND METHODS
mHag HA-l-spec$c CTL clones. Twelve mHag HA-l-specific CD8' CTL clones were originally obtained after restimulation of in vivo primed PBLs from three patients suffering from GVHD after HLA identical but mHag nonidentical BMT. ' The post BMT CTL lines were cloned by limiting dilution, resulting in the isolation of a large number of mHag-specific CTL clones.' Among the latter series of clones, seven clones from donor Ha (patient I in reference 3), four clones from donor Gy (patient IV in reference 3), and one clone from donor Wi (patient V in reference 3) were selected for the TCR analyses on the basis of their concordant reaction patterns against 100 HLA-A2+ target cells and against 25 HLA-A2+ families 2. 3 The HLA types and the clone designations of donors Ha, Gy, and Wi are depicted in Table 1 .
T-cell receptor V-region analysis. Five X IO6 to 10 X 10' cultured CTL were purified by centrifugation through a Ficoll Isopaque gradient. After washing with Hanks' balanced salt solution (HBSS; GIBCO, Paisley, Scotland) the cells were pelleted by centrifugation and stored at -80°C for the molecular analyses. Total RNA was extracted using the RNAzol method (CinnaBiotecx Laboratories, Houston, TX).
Five micrograms of total RNA was transcribed into first-strand cDNA in 25 pL reaction mixture by reverse transcriptase using oligo dT as a primer (Promega Corp, Madison, WI).
TCRa-and TCRP-chain encoding cDNAs were amplified by using 28 different TCRAV and 24 different TCRBV family-specific oligonucleotides using the methodology as described previously.' '." For these polymerase chain reactions, 0.5 to 1.0 pL of cDNA was added to a polymerase chain reaction (PCR) mixture containing 10 mmol/L TRIS-HCl pH 8.4, 50 mmol/L KCl, 4 mmol/L MgC12, 0.06 mg/mL bovine serum albumin (BSA), 0.5 mmol/L of each deoxyadenosine triphosphate (dATF'), deoxycytidine triphosphate, deoxyguanosine triphosphate, and deoxythymidine triphosphate, 2.5 U of Taq DNA polymerase (Perkin-Elmer Cetus, Emeryville, CA), 20 pmol of a TCR 3'C-region primer and 20 pmol of a TCR Vfamily-specific 5' primer in a final volume of 100 pL. AS an internal conrrol for total amplification, a reaction tube containing a 3' and 5' C-region primer was included. Each reaction mixture was overlaid with 50 pL of mineral oil (Sigma, St Louis, MO) before PCR reaction in a DNA thermal cycler (Thermocycler 60; Biomed Instruments, Fullerton, CA). TCRaV-and TCRPV-specific sequences were amplified for 30 and 25 cycles, respectively. Each cycle consisted of 1 minute denaturation at 95"C, 1 minute annealing at 5 5 T , and 1 minute extension at 72°C. After 30 (TCRaV) or 25 (TCMV) cycles of PCR, the products were size fractionated by gel electrophoresis in an 1% agarose gel. The desired PCR-products were captured in 1% low melting-point agarose, and the DNA was recovered using the Magic PCR-Preps DNA purification System (Promega). The purified DNA was used as template in a PCR-based direct dideoxy chain termination sequencing reaction (Circumvent Thermal Cycle Dideoxy DNA sequencing kit; New England Biolabs, Beverly, MA) with 33P-a dATP (Du Pont New England Nulear, Stevenage, UK) according to the instructions of the manufacturer. The sequencing reaction products were separated on 6% polyacrylamidehrea gels and after drying, exposed to Kodak XAR film (Eastman Kodak, Rochester, NY).
The obtained sequences were analyzed using the PCGENE DNA software package (Intelligenetics Inc. Mountain View, CA) to determine TCR and N-(D)-N regions by comparison with the EMBL/ GenBank data enmes.
RESULTS
The TCR V-gene usage of 12 m a g HA-l-specific T-cell clones, which were derived from three unrelated individuals was investigated by PCR using TCRaV and TCRPV-family 2479 specific oligonucleotides. The structure of the TCR V-region was subsequently determined by DNA sequence analysis of the PCR products. The DNA sequence analysis showed the exclusive usage of the TCROV6S9 family member by all 12 M a g HA-l specific CTL (Table 2) .
When the different TCRPV region sequences were compared, a number of striking features emerged. Among the 12 CTL clones, five different types of clones were determined. Nonetheless, striking similarities were observed among these different clones. The two independent sequences of the clones X, Y , I, and R of donor Gy were almost identical, differing only in four nucleotides in the N-D-N-regions. Both types of clones shared the LV amino acid pair (Table 2) . When comparing the T-cell clones derived from donor Gy with the clones B, S, T, and U of donor Ha, a remarkable similarity in the nucleotide composition within the N-D-N region was found that also resulted in the incorporation of an LV amino acid pair in the N-D-N regions of these CTL clones ( Table 2 ). Conservation of a second amino acid pair, ST, is also shared among two types of CTL clones A, V, and W of donor Ha and in clone C of donor Wi. We noted that the CD3-regions of the T-cell clones derived from Gy and Ha were identical in length. This was in contrast with Wi, which exhibited a much longer CD3 region. Analysis of the TCRaV-regions showed the usage of multiple TCRaV genes ( Table 3 ). The TCRa chains of donor Gy were of variable composition. This was in contrast with donor Ha, whose mHag HA-l CTL clones expressed identical TCRaV genes, but different TCRaJ elements. Like for the TCRP chain, the N region of the TCR Va chain of the d a g HAl-specific CTL clone of Wi was much longer than that of the other clones analyzed.
Taken together, these data suggest strong conservation in the TCRPV region used in the recognition of HLA-A*0201/ mHag HA-l complex, whereas the TCRaV regions display a more interindividual heterogeneity.
DISCUSSION
MHC class I antigen presentation has shown strict properties with respect to the structural requirements of the (naturally processed) peptides that are bound into the groove of the MHC m~l e c u l e . '~"~ A number of studies have shown that the T-cell response against these MHC class Upeptide complexes is restricted.
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In the CTL response against peptide antigens derived from virus-encoded proteins, skewed usage of particular TCR V genes was found. This is examplified by the predominant usage of TCRaV and TCRPV regions by HLA-A*0201-and B27-restricted influenza A virus-encoded peptide antigens, established from peripheral blood mononuclear cells (PBMCs) of different donors.4,' Likewise, 9 of 10 clones established at different time points from PBMCs from a single human immunodeficiency virus type 1 (HIV-1)-infected individual used identical TCRaV TCRPV regions.*" Moreover, analyses of T-cell antigen receptor repertoire in the PBLs from six HIV-infected individuals showed major oligoclonal expansions of certain TCRPV families. It appeared that cells expressing the latter TCRPV were of the CD8 type and mediated HIV cytotoxicicity.*' Also among melanoma, HLA-A2-restricted tumor-infiltrating T lymphocytes predominant usage of TCRV regions was found,' whereas in HLA-B27 allorecognition, the TCRa and TCRP chain repertoires exhibit a skewed usage pattern of TCRV genes."
Our study comprised 12 HLA-A*0201 -restricted mHag HA-l-specific CTL clones from three HLA nonidentical unrelated individuals. Although the nature of the mHag HA-l is still elusive, several striking features with respect to Tcell recognition have emerged from our study. First, several CTL clones, obtained from independent limiting dilutions, from individuals Gy and Ha shared fully identical TCRa and TCRP chain sequences. These observations support our notion on the in vitro immunogenic potency and the possible in vivo immunodominant behavior of mHag HA-l during the acute phase of GVHD after BM".' ' (and manuscript submitted for publication). Naturally, a point of caution must be made. Although the twelve CTL clones analyzed in this study were obtained from independent limiting dilutions, there exists a possibility that in vitro expansion may preferentially select for some clones and not for others. Nonetheless, a number of studies investigating the TCR gene usage of PBL from patients post BMT, showed in vivo clonal expansion of several T-cell subpopulations at the time of GVHD.'"' Analyses at the site of inflammation (ie, the skin) show significant higher recurrent TCR transcripts when compared with paired samples of patient PBMCs."' Second, and most striking, the mHag HA-l TCRPV regions expressed by the CTLs, originating from HLA-nonidentical unrelated individuals, share extensive sequence homologies in particular within the N-D-N regions. It suggests a strong selection of TCRPV regions in particular in the mHag HA-IMLA-A*0201 complex recognition. This could be related to the as-yet-unknown nature of the mHag HA-l peptide that play a pivotal role in the outcome of BMT.
To our knowledge, this is the first evidence in humans of interindividual extensive conservation in TCRPV-chain usage for the recognition of an intracellular biosynthesized peptide presented by an MHC class I molecule.
